Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TenoMiR
- Development stage
- Phase 2
- Lead developer
- Causeway Therapeutics
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Local Injection
01
Overview
TenoMiR is a chemically synthesized mimic of microRNA-29a (miR29a) developed as a microRNA replacement therapy for tendinopathy, including conditions such as lateral epicondylitis (tennis elbow). It is designed to restore miR29a levels in injured tendons, directly targeting the key changes in collagen production that underlie tendon degeneration. By restoring normal collagen synthesis and organization, TenoMiR aims to promote tendon healing and regeneration. The drug has demonstrated improved stability, activity, and cellular uptake while being non-immunogenic. In preclinical models and early clinical trials (Phase 1b), single local injections of TenoMiR have shown safety and efficacy in improving tendon structure. A Phase 2 multicenter clinical trial is ongoing to further evaluate its efficacy and safety in patients with lateral epicondylitis[1][2][6][7].
Beyond the preview
Go deeper on TenoMiR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TenoMiR.